RecruitingAlzheimer's Disease
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
Sponsor: Eisai Co., Ltd.
You may qualify if…
- ✓ All participants who are treated with lecanemab in routine clinical practice
You may not qualify if…
- ✕ None
Source: ClinicalTrials.gov · NCT06322667 · last updated 2026-01-23